KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Ingredients (ALTO) Asset Writedowns and Impairment (2017 - 2025)

Alto Ingredients (ALTO) has 14 years of Asset Writedowns and Impairment data on record, last reported at -$1.7 million in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 6787.5% year-over-year to -$1.7 million; the TTM value through Sep 2025 reached -$31000.0, down 105.57%, while the annual FY2024 figure was -$50000.0, 108.71% down from the prior year.
  • Asset Writedowns and Impairment reached -$1.7 million in Q3 2025 per ALTO's latest filing, down from $479000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.9 million in Q2 2021 and bottomed at -$1.7 million in Q3 2025.
  • Average Asset Writedowns and Impairment over 5 years is $177368.4, with a median of -$3000.0 recorded in 2021.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 10455.56% in 2021, then tumbled 8333.33% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $18000.0 in 2021, then plummeted by 266.67% to -$30000.0 in 2022, then skyrocketed by 2193.33% to $628000.0 in 2023, then crashed by 104.3% to -$27000.0 in 2024, then tumbled by 6022.22% to -$1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were -$1.7 million in Q3 2025, $479000.0 in Q2 2025, and $1.2 million in Q1 2025.